Sensorion receives European Medicines Agency agreement on the Pediatric Investigation Plan (PIP) for Arazasetron  (SENS-401) in two indications. pdfRead

Pipeline

20190603 pipeline

Enregistrer

Patient center

Corporate presentation

Next events